Throughout the last three months, 6 analysts have evaluated Harmony Biosciences HRMY, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 3 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Harmony Biosciences, revealing an average target of $38.5, a high estimate of $53.00, and a low estimate of $26.00. Observing a downward trend, the current average is 30.63% lower than the prior average price target of $55.50.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Harmony Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jason Gerberry | B of A Securities | Announces | Underperform | $30.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $53.00 | - |
| Danielle Brill | Raymond James | Raises | Outperform | $27.00 | $26.00 |
| David Amsellem | Piper Sandler | Lowers | Overweight | $42.00 | $72.00 |
| Ami Fadia | Needham | Lowers | Buy | $53.00 | $66.00 |
| Danielle Brill | Raymond James | Lowers | Outperform | $26.00 | $58.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Harmony Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Harmony Biosciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Harmony Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Harmony Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Harmony Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Harmony Biosciences: A Closer Look
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Financial Milestones: Harmony Biosciences's Journey
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Harmony Biosciences displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 36.74%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Harmony Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.0% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Harmony Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of 7.96%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Harmony Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of 5.0%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Harmony Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
